Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)
Accession Number
DB14385
Description

A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.

There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.

Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Inactivated
Synonyms
Not Available

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Abatacept.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) is combined with Acetylsalicylic acid.
AdalimumabThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Adalimumab.
AldesleukinThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Aldesleukin.
AlefaceptThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Alefacept.
AlemtuzumabThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab.
AltretamineThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Altretamine.
Aminosalicylic acidThe risk or severity of adverse effects can be increased when Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) is combined with Aminosalicylic acid.
AmsacrineThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Amsacrine.
AnakinraThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Anakinra.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Active Moieties
NameKindUNIICASInChI Key
Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)unknownW45Z4CJE2JNot AvailableNot applicable
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
FluarixInfluenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Brisbane/59/2007 (H1N1) hemagglutinin antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Uruguay/716/2007(H3N2) hemagglutinin antigen (formaldehyde inactivated) (15 ug/0.5mL)SuspensionIntramuscularGlaxoSmithKline Biologicals SA2009-07-162009-07-15US flag
Fluarix 2010/2011Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) (15 ug/0.5mL)SuspensionIntramuscularGlaxoSmithKline Biologicals SA2010-08-092010-08-02US flag

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
166D8OWM7B
CAS number
Not Available

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingPreventionFlu caused by Influenza1
4CompletedBasic ScienceInfluenza A Subtype H5N1 Infection1
4CompletedOtherAsthma / Influenza Vaccines in Asthma Populations1
4CompletedPreventionFlu caused by Influenza5
4CompletedPreventionFlu caused by Influenza / Influenza Infection2
3Active Not RecruitingPreventionFlu caused by Influenza1
3CompletedPreventionAcellular Pertussis / Diphtheria / Flu caused by Influenza / Pertussis / Tetanus1
3CompletedPreventionFlu caused by Influenza19
3CompletedPreventionFlu caused by Influenza / Influenza A Virus, H1N1 Subtype / Influenza Infection1
3CompletedPreventionFlu caused by Influenza / Influenza Disease / Influenza Vaccines1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SuspensionIntramuscular
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on July 05, 2018 12:02 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates